San Francisco, February 27 (By Suvarna Bhatt, BioSpace) – Perth, Australia based biotechnology company bioMD Limited, announces that its subsidiary, Celxcel Pty Ltd, reports promising results from a Sheep Implant Trial of tissue patches treated by its proprietary ADAPT tissue engineering process. The company plans to move into phase 1 human clinical trials with ADAPT treated Kangaroo and Bovine pericardium tissue patches.
